Trending Now
Allena Pharmaceuticals Inc (NASDAQ:ALNA) Increases Bought Deal Offering To $6.7 Million:...
Allena Pharmaceuticals Inc (NASDAQ:ALNA) narrowed net loss by 61.4% to $7 million in Q2 2020. Its cash/ cash equivalents declined to $26.5 million in...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Acasti Pharma Inc (NASDAQ:ACST) Receives The FDA’s Written Response Regarding Request...
Acasti Pharma Inc (NASDAQ:ACST) has announced that the Food and Drug Administration (FDA) responded to its request for a TRILOGY 1 Briefing Package, as...
MAKE IT MODERN
LATEST REVIEWS
Abeona Therapeutics Inc. (NASDAQ:ABEO) Says It IS Resuming Patient Enrollment in...
Abeona Therapeutics Inc. (NASDAQ:ABEO) is about to begin patient enrollment in its pivotal Phase 3 VITAL study of EB-101. The enrollment is resuming after...
MAKE IT MODERN
PERFORMANCE TRAINING
Atossa Therapeutics Inc (NASDAQ:ATOS) Commences Treatment Of A Patient With Ovarian Cancer Using Its...
Atossa Therapeutics Inc (NASDAQ:ATOS) began treating an ovarian cancer patient with its oral Endoxifen under an expanded pathway permitted previously by the US FDA.
Surgeon-in-Chief,...
bluebird bio Inc (NASDAQ: BLUE) Announces Q2 2022 Financial Results And Updates on beti-cel...
bluebird bio Inc (NASDAQ: BLUE) has announced its Q2 2022 financial results and offered business highlights for the quarter ending June 30, 2022.
bluebird bio...
Aileron Therapeutics Inc (NASDAQ:ALRN) Raises $10.3 Million: Develops Innovative Medicine To Safeguard Cancer Patients...
Aileron Therapeutics Inc (NASDAQ:ALRN) develops innovative chemoprotective medicine to safeguard patients from side effects and toxicities induced by chemotherapy.
CEO of Aileron, Manuel Aivado, said...
Is today’s gains on Nuburu Inc (NASDAQ:BURU) justified ?
Nuburu Inc (NASDAQ:BURU) is currently trading at $4.9625, up more than +2.2425 (+82.44%)
The stock opened today at a...
Progenity Inc. (NASDAQ: PROG) To Present Two Abstracts At The 17th Congress of the...
Progenity Inc. (NASDAQ: PROG) has announced the acceptance of two presentations with patient findings on indicators of efficacy on gastrointestinal disorders treatment by the...
MAKE IT MODERN
